Liquid Biopsy Could Identify Advanced Breast Cancer Patients
By LabMedica International staff writers Posted on 09 Aug 2017 |
Image: The Ion Ampliseq library preparation kits (Photo courtesy of Thermo Fisher Scientific).
A novel blood test has been developed that measures genetic changes in circulating cancer DNA that could help identify patients with metastatic breast cancer who could benefit from a change of treatment.
Somatic mutation profiling of breast tumor tissues has identified a number of distinct breast cancer molecular subtypes characterized by diverse somatic mutations, including single nucleotide variants (SNVs) and copy number alterations (CNAs).
Scientists at the University of Leicester (Leicester, UK) recruited 42 patients with radiological-confirmed metastatic breast cancer (MBC) and nine women attending for breast screening mammography as age-matched controls. Blood samples were collected and the plasma processed using the Circulating Nucleic Acids kit.
The team designed a custom 158-amplicon panel (size range 125–175 bp) across 16 genes based on previous studies and publically available databases. Library preparation and Personal Genome Machine (PGM) sequencing were performed using the Ion Ampliseq library preparation kit. Droplet digital polymerase chain reaction (ddPCR) was used to validate tumor protein p53 (TP53), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), and estrogen receptor 1 (ESR1) mutations.
The scientists identified no mutations in cell free DNA (cfDNA) of healthy controls, whereas exactly half the patients with metastatic breast cancer had at least one mutation or amplification in cfDNA (mean 2, range 1–6) across a total of 13 genes. Longitudinal follow up showed dynamic changes to mutations and gene amplification in cfDNA indicating clonal and subclonal response to treatment that was more dynamic than cancer antigen 15-3 (CA15-3).
At the time of blood sampling disease progression was occurring in seven patients with erb-b2 receptor tyrosine kinase 2 (ERBB2) gene amplification in their cfDNA and three of these patients were human epidermal growth factor receptor 2 (HER2) negative at diagnosis, suggesting clonal evolution to a more aggressive phenotype. Six of the women with hormone-driven cancers had mutations in the ESR1 gene, which has been linked to resistance to anti-hormone treatments.
David Guttery, PhD, a leading author of the study, said, “We have developed a novel blood test that can simultaneously detect somatic mutations and copy number alterations that are integral in driving the growth of breast cancer. By analyzing blood plasma to measure for cancer-specific changes to key breast cancer genes, including the HER2 and estrogen receptor genes, we hope this test could help doctors and patients choose the best treatment at the best time.” The study was described by Professor Jacqui A. Shaw, PhD, in an oral presentation at the Frank May Prize Lecture on June 26, 2017, at the University of Leicester.
Related Links:
University of Leicester
Somatic mutation profiling of breast tumor tissues has identified a number of distinct breast cancer molecular subtypes characterized by diverse somatic mutations, including single nucleotide variants (SNVs) and copy number alterations (CNAs).
Scientists at the University of Leicester (Leicester, UK) recruited 42 patients with radiological-confirmed metastatic breast cancer (MBC) and nine women attending for breast screening mammography as age-matched controls. Blood samples were collected and the plasma processed using the Circulating Nucleic Acids kit.
The team designed a custom 158-amplicon panel (size range 125–175 bp) across 16 genes based on previous studies and publically available databases. Library preparation and Personal Genome Machine (PGM) sequencing were performed using the Ion Ampliseq library preparation kit. Droplet digital polymerase chain reaction (ddPCR) was used to validate tumor protein p53 (TP53), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), and estrogen receptor 1 (ESR1) mutations.
The scientists identified no mutations in cell free DNA (cfDNA) of healthy controls, whereas exactly half the patients with metastatic breast cancer had at least one mutation or amplification in cfDNA (mean 2, range 1–6) across a total of 13 genes. Longitudinal follow up showed dynamic changes to mutations and gene amplification in cfDNA indicating clonal and subclonal response to treatment that was more dynamic than cancer antigen 15-3 (CA15-3).
At the time of blood sampling disease progression was occurring in seven patients with erb-b2 receptor tyrosine kinase 2 (ERBB2) gene amplification in their cfDNA and three of these patients were human epidermal growth factor receptor 2 (HER2) negative at diagnosis, suggesting clonal evolution to a more aggressive phenotype. Six of the women with hormone-driven cancers had mutations in the ESR1 gene, which has been linked to resistance to anti-hormone treatments.
David Guttery, PhD, a leading author of the study, said, “We have developed a novel blood test that can simultaneously detect somatic mutations and copy number alterations that are integral in driving the growth of breast cancer. By analyzing blood plasma to measure for cancer-specific changes to key breast cancer genes, including the HER2 and estrogen receptor genes, we hope this test could help doctors and patients choose the best treatment at the best time.” The study was described by Professor Jacqui A. Shaw, PhD, in an oral presentation at the Frank May Prize Lecture on June 26, 2017, at the University of Leicester.
Related Links:
University of Leicester
Latest Molecular Diagnostics News
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer
- Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer
- Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer
- Simple PCR Assay Accurately Differentiates Between Small Cell Lung Cancer Subtypes
- Revolutionary T-Cell Analysis Approach Enables Cancer Early Detection